Clinical Trials
13 trialsNCT03601442 2026-04-23
Managed Access Programs for CTL019, Tisagenlecleucel
Novartis
Available
NCT01881334 2025-11-20
Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants
Duke University
Available
NCT04809233 2025-06-04
Expanded Access to Tipifarnib
Kura Oncology, Inc.
Available
NCT02822495 2023-06-15
Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies
Atara Biotherapeutics
No longer available
NCT05733650 2023-05-25
Expanded Access Program for Epcoritamab
Genmab
Approved for marketing
NCT05692050 2023-02-03
Expanded Access to Epcoritamab
AbbVie
No longer available
NCT01200017 2021-05-27
Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant
University of California, San Francisco
No longer available
NCT04705454 2021-05-12
Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
ADC Therapeutics S.A.
No longer available
NCT01196208 2020-09-21
A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001
Seagen Inc.
No longer available
NCT02715843 2019-10-11
Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma
Molecular Templates, Inc.
No longer available
NCT00423826 2016-02-29
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
Barbara Ann Karmanos Cancer Institute
No longer available
NCT00481559 2014-01-17
Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity
BTG International Inc.
Approved for marketing
NCT00517894 2007-08-17
Dose-Dense Therapy in Aggressive Lymphoma
Arbeitsgemeinschaft medikamentoese Tumortherapie
No longer available